Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 NFXLcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXKXHlHOC53IN88US=> NWL2W2JYPzJiaB?= MknNSG1UVw>? MmXYTWM2OD1yLkC0JO69VQ>? NV;YNFNqOjZzM{[2PFQ>
LS174T NWjrZ4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO2NE42KM7:TR?= NGTsdpA4OiCq MlW0SG1UVw>? M360c2lEPTB;MD6wOUDPxE1? Mni5NlYyOzZ4OES=
T84 M4XnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXTNE42KM7:TR?= MX[3NkBp M4Tu[WROW09? NWj4cXNtUUN3ME2wMlA6KM7:TR?= NULQcIdEOjZzM{[2PFQ>
LS180 NU\0[mYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETNfI4xNjVizszN MVq3NkBp MV7EUXNQ MVrJR|UxRTFizszN MkLrNlYyOzZ4OES=
SW948 M1fwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrJSJIxNjVizszN M2rIeFczKGh? NVi2d5RXTE2VTx?= NYL5Npd5UUN3ME2xJO69VQ>? MWiyOlE{PjZ6NB?=
HCT15 NHXzT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7NNE42KM7:TR?= NI\TbI04OiCq NYrqTWtOTE2VTx?= MUDJR|UxRDBwNDFOwG0> Mlr5NlYyOzZ4OES=
DLD-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL2PHZPOC53IN88US=> MlzaO|IhcA>? M3fkTmROW09? M3jQSmlEPTB:MD64JO69VQ>? MXWyOlE{PjZ6NB?=
MIP-101 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonJNE42KM7:TR?= MYG3NkBp MofpSG1UVw>? NUnMU41JUUN3ME2xJO69VQ>? NEPvbGQzPjF|Nk[4OC=>
SNU1544 M331XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OwWFAvPSEQvF2= MYS3NkBp NGLnPY5FVVOR MYnJR|UxRTFizszN MYCyOlE{PjZ6NB?=
OCI-Ly10 MWLDfZRwfG:6aXOgRZN{[Xl? NWnI[Vc4PzJiaB?= M4fSNmROW09? NVfB[pRtUUN3ME2wMlA2QCEQvF2= NWO4XJNROjV6N{izN|E>
SU-DHL2 M3n5fmN6fG:2b4jpZ{BCe3OjeR?= M2f6OFczKGh? NXjLZpU6TE2VTx?= NYDPTZA4UUN3ME2wMlAyKM7:TR?= NEXZOZgzPTh5OEOzNS=>
OCI-LY7 MoXpR5l1d3SxeHnjJGF{e2G7 MXq3NkBp MV;EUXNQ M4fTPWlEPTB;MD6wPFEh|ryP M1fwTVI2QDd6M{Ox
SU-DHL6 MWPDfZRwfG:6aXOgRZN{[Xl? MVy3NkBp NY[4PHhqTE2VTx?= M2Lae2lEPTB;MD60PFIh|ryP MnfnNlU5Pzh|M{G=
Jeko-1 MlTrR5l1d3SxeHnjJGF{e2G7 MnrvO|IhcA>? MUPEUXNQ M3\2[GlEPTB;MD6wNlkh|ryP MYWyOVg4QDN|MR?=
JVM-2 MmPKR5l1d3SxeHnjJGF{e2G7 NUnWT5Q6PzJiaB?= NIq2VXdFVVOR MVrJR|UxRTBwMEGg{txO MWGyOVg4QDN|MR?=
Rec-1 NYrOeYM{S3m2b4TvfIlkKEG|c3H5 NUjycHY3PzJiaB?= NXKwNJpDTE2VTx?= M3Pl[GlEPTB;MD6wPFch|ryP MVqyOVg4QDN|MR?=
Z-138 Ml7KR5l1d3SxeHnjJGF{e2G7 M1u4eFczKGh? NX\RUGd2TE2VTx?= M{PuWmlEPTB;MD6wNVMh|ryP NYjIOlFnOjV6N{izN|E>
H9 NGfpc2tEgXSxdH;4bYMhSXO|YYm= M4PhVVczKGh? MnjjSG1UVw>? MmTmTWM2OD1yLk[g{txO MVeyOVg4QDN|MR?=
HH NV\pTmdYS3m2b4TvfIlkKEG|c3H5 NV\pTlVKPzJiaB?= MU\EUXNQ NEfpTmdKSzVyPUCuO{DPxE1? NF7DTJgzPTh5OEOzNS=>
DND41 MonmR5l1d3SxeHnjJGF{e2G7 MlnDO|IhcA>? MYfEUXNQ MYnJR|UxRTBwMTFOwG0> M1XHT|I2QDd6M{Ox
CCL119 NVu5N4pOS3m2b4TvfIlkKEG|c3H5 NFLZdVM4OiCq MXjEUXNQ M4jzemlEPTB;MD6wOlIh|ryP MX[yOVg4QDN|MR?=
J.Cam 1.6 M{izfWN6fG:2b4jpZ{BCe3OjeR?= M4nldlczKGh? NYLYOYpHTE2VTx?= NGLPSohKSzVyPUCuNVA2KM7:TR?= NE\iZVgzPTh5OEOzNS=>
Sup-T1 MlLsR5l1d3SxeHnjJGF{e2G7 MWC3NkBp NX;Od3lpTE2VTx?= MVjJR|UxRTJwMUSyJO69VQ>? NWrHS3ZwOjV6N{izN|E>
Tib 152 NXHCdFk4S3m2b4TvfIlkKEG|c3H5 MV:3NkBp NWHGfFJVTE2VTx?= NVq0dZVuUUN3ME2wMlgh|ryP NFKzZ4MzPTh5OEOzNS=>
MCF7 M334cmZ2dmO2aX;uJGF{e2G7 NWXCelN1PSEQvF2= NVPjeFRuOjRiaB?= MkXMSG1UVw>? NVzsfXViUW6mdXPld{BIOi:PIHHydoV{fA>? MYKyOVg{PDRyMR?=
MDA-MB-231 MXPGeY5kfGmxbjDBd5NigQ>? NUCxb3FEPSEQvF2= M1u4ZVI1KGh? MXXEUXNQ MUjJcoR2[2W|IFezM20h[XK{ZYP0 NXjZNYlEOjV6M{S0NFE>
MCF7 NVLxfYRMTnWwY4Tpc44hSXO|YYm= NHXXSJU2KM7:TR?= M{nBV|I1KGh? MV\EUXNQ MWPE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ NVjKRpBvOjV6M{S0NFE>
MCF7 MlO0SpVv[3Srb36gRZN{[Xl? M4fMbFUh|ryP NVmx[IxwOjRiaB?= NV62V2RKTE2VTx?= M4PQVWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz MnzxNlU5OzR2MEG=
MCF7 MX\GeY5kfGmxbjDBd5NigQ>? MVS1JO69VQ>? MmXqNlQhcA>? MULEUXNQ NIn5N3RF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx MorkNlU5OzR2MEG=
MCF7 NILNTYVHfW6ldHnvckBCe3OjeR?= NF:3e282KM7:TR?= M3j6cVI1KGh? NVLofFY3TE2VTx?= MmHSTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> MYeyOVg{PDRyMR?=
MCF7 NWTqNYE6TnWwY4Tpc44hSXO|YYm= NFnCUWg2KM7:TR?= M1jiW|I1KGh? NVvHOmtbTE2VTx?= MnTMTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyO{BMcXBz NEnPepAzPTh|NESwNS=>
MDA-MB-231 NX25NVgyTnWwY4Tpc44hSXO|YYm= NEWyTYY2KM7:TR?= NEjvfnMzPCCq NXPrUlF3TE2VTx?= NETySFFF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy MnrmNlU5OzR2MEG=
MDA-MB-231 NGrBXoNHfW6ldHnvckBCe3OjeR?= NHHiZYYyKM7:TR?= MXOyOEBp NH;ZfGtFVVOR NGTYNGVKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>? NVm1[pVUOjV6M{S0NFE>
MDA-MB-231 M4nWSWZ2dmO2aX;uJGF{e2G7 NITXd3k2KM7:TR?= NUH1R45qOjRiaB?= MYjEUXNQ NHzjXZJF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx NFzoTpgzPTh|NESwNS=>
MDA-MB-231 M1jRUmZ2dmO2aX;uJGF{e2G7 NY\BVVhzPSEQvF2= MU[yOEBp NGi1TnJFVVOR NFPSVWJKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? MVGyOVg{PDRyMR?=
MDA-MB-231 MlWySpVv[3Srb36gRZN{[Xl? M3\Y[FUh|ryP MnrYNlQhcA>? MUHEUXNQ NUXwRVk6UW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx M335WlI2QDN2NECx
MDA-MB-231 MljUSpVv[3Srb36gRZN{[Xl? NVjHVJVHPSEQvF2= M1;MWFI1KGh? M2HxcWROW09? Ml34TY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=> Mnz3NlU5OzR2MEG=
MCF7 Mnq5RZBweHSxc3nzJGF{e2G7 NHHYfZY2KM7:TR?= M1;pW|I1KGh? MVvEUXNQ MVfJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? MorDNlU5OzR2MEG=
MDA-MB-231 NVfsS25VSXCxcITvd4l{KEG|c3H5 NWDKVYFEPSEQvF2= NXO2[JFIOjRiaB?= NXjUc5VpTE2VTx?= MX;JcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? MYqyOVg{PDRyMR?=
MCF7 MnjkSpVv[3Srb36gRZN{[Xl? NWizUYs1OSEQvF2= MWG3NkBp NUT1OY0yTE2VTx?= M1;NPWlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= M4LzV|I2QDN2NECx
MDA-MB-231 MYDGeY5kfGmxbjDBd5NigQ>? NE\LPW4yKM7:TR?= M13nfFczKGh? MVzEUXNQ NFKyd4lKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= MYGyOVg{PDRyMR?=
U-2 OS MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvjOVAh|ryP MV2yOEBp MoPxSG1UVw>? NGXyUmtKSzVyPUG2MlYh|ryP NWX2VJVmOjV5OUK4NVE>
MG-63 NXvkTGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK1NEDPxE1? M3;le|I1KGh? NInEOYFFVVOR M1zp[mlEPTB;OT61JO69VQ>? MkT5NlU4QTJ6MUG=
U-2 OS MV7BdI9xfG:|aYOgRZN{[Xl? MUK1JO69VQ>? NGXldI8zPCCq NGLCTY9FVVOR NWPsRVl{UW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? MmrlNlU4QTJ6MUG=
MG-63 MXjBdI9xfG:|aYOgRZN{[Xl? Mn;QOUDPxE1? M1Hre|I1KGh? NX;qT5l2TE2VTx?= NX\RTphrUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? MXuyOVc6OjhzMR?=
U-2 OS Mo\uSpVv[3Srb36gRZN{[Xl? MknhOUDPxE1? M1;PO|I1KGh? M3vtOWROW09? MXHQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> Ml;KNlU4QTJ6MUG=
MG-63 MlnRSpVv[3Srb36gRZN{[Xl? MljzOUDPxE1? M{nuZVI1KGh? MUXEUXNQ MXvQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> NH60PHIzPTd7MkixNS=>
PANC-1 NXzqW|JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXXV3hsPTBizszN MkTDNlQhcA>? MXXEUXNQ NIjsbFlKSzVyPUeuNUDPxE1? MWmyOVY{OjJ{NR?=
BxPC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrDOVAh|ryP NE[5OYszPCCq M4fkeGROW09? MYjJR|UxRTZwODFOwG0> MnrONlU3OzJ{MkW=
PANC-1 NYnVcXgxTnWwY4Tpc44hSXO|YYm= MnO1OUDPxE1? NGHmOGozPCCq NX2zXmF4TE2VTx?= NWfXfW9PUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn MVWyOVY{OjJ{NR?=
BxPC-3 NFvJd4xHfW6ldHnvckBCe3OjeR?= MWC1JO69VQ>? NXPRfIFPOjRiaB?= MUXEUXNQ NYW0fnVNUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn NUHRbpBmOjV4M{KyNlU>
PANC-1 Ml\ISpVv[3Srb36gRZN{[Xl? NFixbFA2KM7:TR?= M3vv[FI1KGh? NF\0[IFFVVOR MXvJcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> NUTmV3JqOjV4M{KyNlU>
BxPC-3 MnvOSpVv[3Srb36gRZN{[Xl? MWS1JO69VQ>? NFKzcHgzPCCq M2P4fGROW09? M{HEWWlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp MkDENlU3OzJ{MkW=
SKOV3 M{\Pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISzS2wyODBizszN MVuyOEBp MVLEUXNQ M1rSXmlEPTB;MkCuOFgh|ryP NGrKbm0zPTZ{NEe1NC=>
OVCAR4 NFy5[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S3S|ExOCEQvF2= M{XPe|I1KGh? M{DFVmROW09? NYLjZ5kyUUN3ME2yNk4yOyEQvF2= MXGyOVYzPDd3MB?=
SKOV3 NV3DenlHTnWwY4Tpc44hSXO|YYm= MXW1JO69VQ>? M3\qZVczKGh? NHz2VIJFVVOR MWDJcoR2[2W|IFeyM20h[XK{ZYP0 NVzt[G9wOjV4MkS3OVA>
OVCAR4 Mn\iSpVv[3Srb36gRZN{[Xl? MnjvOUDPxE1? M4HyNVczKGh? M4ftZmROW09? MnrNTY5lfWOnczDHNk9OKGG{cnXzeC=> MlG1NlU3OjR5NUC=
SKOV3 MU\BdI9xfG:|aYOgRZN{[Xl? NU\ONIhTPSEQvF2= NHnOXlIzPCCq Ml;hSG1UVw>? M{\PUWlv\HWlZYOgZZBweHSxc3nz NWHFfGlxOjV4MkS3OVA>
OVCAR4 NH\5ZlJCeG:ydH;zbZMhSXO|YYm= MV:1JO69VQ>? NGPRZVUzPCCq NFnPV4VFVVOR NIrSdFFKdmS3Y3XzJIFxd3C2b4Ppdy=> MUGyOVYzPDd3MB?=
AGS MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHpSXkzPSEQvF2= NF3S[3ozPCCq NHf6OotFVVOR M{C3Z2lEPTB;MUmuNFkh|ryP MlTENlU3ODl7MkO=
NCI-N78 M2H4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvNVYZFOjVizszN M4nBbFI1KGh? MWrEUXNQ NU\CV4FXUUN3ME2yOk4{OyEQvF2= MoTkNlU3ODl7MkO=
AGS NYPQc486SXCxcITvd4l{KEG|c3H5 Mnn4OUDPxE1? NHOwXlkzPCCq MXvEUXNQ NWSyd5RVUW6mdXPld{BieG:ydH;zbZM> NIXUfIszPTZyOUmyNy=>
NCI-N78 MlX4RZBweHSxc3nzJGF{e2G7 NEfuWFU2KM7:TR?= NFq0SWszPCCq MX\EUXNQ M{HXZWlv\HWlZYOgZZBweHSxc3nz M3P6WlI2PjB7OUKz
AGS NWXzO4h{TnWwY4Tpc44hSXO|YYm= NGXy[Y82KM7:TR?= MVOyOEBp NYPONXFCTE2VTx?= MVPJcoR2[2W|IITo[UBifXSxcHjh[5k> MlPaNlU3ODl7MkO=
NCI-N78 NHvtc5NHfW6ldHnvckBCe3OjeR?= NUfVc29kPSEQvF2= NVXtPJhpOjRiaB?= NGHPWoZFVVOR M4WzdGlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? NYPxRY1qOjV4MEm5NlM>
HSC-3 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjpVIsyKM7:TR?= NVfWOGx1PDhiaB?= NVSxPHBZUUN3ME2wMlU1KM7:TR?= NVfnfoVKOjV|Nk[xOFM>
GB30 M4fxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHDb5RIOSEQvF2= NHqxb4E4KGR? MVzEUXNQ MV;JR|UxRTBwMEGxJO69VQ>? NF\WRVEzPTFyNkSyPC=>
GB9 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYexJO69VQ>? NWLp[|NPPyCm NIf4SGtFVVOR M2G0TmlEPTB;MD6wNlQh|ryP MnvMNlUyODZ2Mki=
GB169 M1nkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LnTFEh|ryP MojpO{Bl NUjHZ2R3TE2VTx?= NF7je2pKSzVyPUCuNFMzKM7:TR?= M4P3cVI2OTB4NEK4
T24 M4L1WGZ2dmO2aX;uJGF{e2G7 NUmzSIV2OSEQvF2= NHTTfmg1QCCq NXjR[WltTE2VTx?= NXLBcm9kUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NUTVbJo4OjN2MEO2N|M>
RT4 M3TyTGZ2dmO2aX;uJGF{e2G7 MX[xJO69VQ>? NHPDZWY1QCCq MnfQSG1UVw>? MlPpTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M4PMVFI{PDB|NkOz
UM-UC-3 Ml;iSpVv[3Srb36gRZN{[Xl? MlnPNUDPxE1? NYDwd4I1PDhiaB?= MlvDSG1UVw>? NUHFcHhLUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MnT5NlM1ODN4M{O=
T24 MorrRZBweHSxc3nzJGF{e2G7 NFviRVI{NjF4IN88US=> NGP5W3A6PiCq M2n4RmROW09? M3TBeGlEPTB;MD6wN|A3KM7:TR?= MYKyN|QxOzZ|Mx?=
RT4 NX3jSnh5SXCxcITvd4l{KEG|c3H5 NEDPe|M{NjF4IN88US=> MmLkPVYhcA>? NYXrWnBpTE2VTx?= MV3JR|UxRTBwMUG5PEDPxE1? M1XzZVI{PDB|NkOz
UM-UC-3 NInmdWZCeG:ydH;zbZMhSXO|YYm= NE\ZZlk{NjF4IN88US=> MUm5OkBp M4ixXmROW09? M1m0e2lEPTB;MD6wOFQ6KM7:TR?= NFX6Wo8zOzRyM{[zNy=>
OVCAR-5 NEPL[HlHfW6ldHnvckBCe3OjeR?= M1XIOVUxKG6P MnfxTY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? M3\6ZlI{OzN2M{K3
SKOV3ip2 M{\XdGZ2dmO2aX;uJGF{e2G7 MU[1NEBvVQ>? M{fpNmlvcGmkaYTzJINmdGxibXnndoF1cW:w NX;BbpFqOjN|M{SzNlc>
S462 NGjBRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDUfFM5OTByIN88US=> Ml;CO|IhcA>? NV\FfHRlTE2VTx?= NVnSVoV2SXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= NFn2dVczOzN{OEGxOC=>
2884 MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\pNVAxKM7:TR?= NUK0[VNGPzJiaB?= MmLWSG1UVw>? M1yzWmF1fGWwdXH0[ZMh[2WubDDndo94fGh? MmrJNlM{OjhzMUS=
2885 NX;RW29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LjPFExOCEQvF2= M2jJflczKGh? NXHRbXg{TE2VTx?= NXnHOJRRSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= M2jlUVI{OzJ6MUG0
CRL-2396 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVixNFAh|ryP MWf3ZZRmeg>? MXrJR|UxRTBwMEmyJO69VQ>? M3fxfFI{OTV|NUK0
TIB-48 NGHDWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H5WFExOCEQvF2= Mo\1e4F1\XJ? M{exVGlEPTB;MD6wPFgh|ryP MnHYNlMyPTN3MkS=
CRL-2396 M1TIRmN6fG:2b4jpZ{BCe3OjeR?= NELLe2cyKM7:TR?= MV:0PEBp M2LUUZdifGW{ MXvJcoR2[2W|IHHwc5B1d3Orcx?= NUHodHVEOjNzNUO1NlQ>
TIB-48 MlK1R5l1d3SxeHnjJGF{e2G7 M2XSdFEh|ryP NVzTU2JVPDhiaB?= NWK5O5o3f2G2ZYK= NWPINXdRUW6mdXPld{BieG:ydH;zbZM> M13PTVI{OTV|NUK0
AGS NUfzS41VS3m2b4TvfIlkKEG|c3H5 MonkNE42KM7:TR?= NEPz[VMzPCCq MVPEUXNQ Mni5SIVkemWjc3XzJINmdGxic4Xyeol3[Wx? M1G4TVIzQTd{NkGx
FLO-1 MlTHR5l1d3SxeHnjJGF{e2G7 NFHhUokxNjVizszN NIDTTlgzPCCq NXjoRlRCTE2VTx?= MVTE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? NITHbYgzOjl5Mk[xNS=>
OE33 NFnEdmFEgXSxdH;4bYMhSXO|YYm= NInLN2ExNjVizszN M2nPW|I1KGh? NYLnOHBoTE2VTx?= NXO0[oxVTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= MoXRNlI6PzJ4MUG=
SKLMS M1PKTWN6fG:2b4jpZ{BCe3OjeR?= MYK3OUBvVQ>? NI\6SIU6PiCq M2fLSWlv\HWlZYOgZZBweHSxc3nz Mnm1NlI5OjF7OUe=
Leio285 M3j5d2N6fG:2b4jpZ{BCe3OjeR?= M2TzeVc2KG6P MXe5OkBp M3W4WWlv\HWlZYOgZZBweHSxc3nz M{TNZVIzQDJzOUm3
Mes-Sa M4rke2N6fG:2b4jpZ{BCe3OjeR?= NGS3WGM4PSCwTR?= M321R|k3KGh? M2XzOGlv\HWlZYOgZZBweHSxc3nz M2D2[VIzQDJzOUm3
DAOY M2jzU2N6fG:2b4jpZ{BCe3OjeR?= MlPUNVAh|ryP NFv0d4c4OiCq NVvYdphVTE2VTx?= MlTUTWM2OD1yLkC0JO69VQ>? NXzYRWJzOjJ4NkmzN|U>
IMR32 NILoeIdEgXSxdH;4bYMhSXO|YYm= NWL6PXZkOTBizszN NHrpU4U4OiCq MWnEUXNQ M3fLW2lEPTB;MD6wN{DPxE1? NXjnbJAyOjJ4NkmzN|U>
Molt-4 M3y2bGN6fG:2b4jpZ{BCe3OjeR?= M1\XZVExKM7:TR?= NHT4[4w4OiCq MYXEUXNQ M3T5[mlEPTB;MD6wNkDPxE1? NHLOcWUzOjZ4OUOzOS=>
MOLM-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCzJO69VQ>? NIT3NZQ4OiCq NFfpUFNFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NV\BOYh4OjJ2OEiyOFk>
HL-60 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i5d|Mh|ryP M3;BdVczKGh? NHjL[4pFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MnGwNlI1QDh{NEm=
MV4-11 M2jaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvzeFNUOyEQvF2= NIHOSok4OiCq NFH3ZplFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NFfPc3UzOjR6OEK0PS=>
SKM-1 M3rsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fkSVMh|ryP MoHMO|IhcA>? M13GO2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= M{fNVFIzPDh6MkS5
SH2 NYHBZo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLQUFl4OyEQvF2= NIDndok4OiCq MorvSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NVfXZokxOjJ2OEiyOFk>
NOMO-1 NH:4cHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOzJO69VQ>? NX7xVpg{PzJiaB?= M2Hye2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NXLmPXRGOjJ2OEiyOFk>
OCL-AML2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXUcVJWOyEQvF2= M1m5WFczKGh? M{nDZWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NGT0OGczOjR6OEK0PS=>
PL-21 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPkWJR2OyEQvF2= Mn\XO|IhcA>? NXzMU49pTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MVGyNlQ5QDJ2OR?=
KG-1 M{HTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OzZ|Mh|ryP NI\PTlU4OiCq M1nwZmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NX\SNlZQOjJ2OEiyOFk>
A172 NEX5fo9EgXSxdH;4bYMhSXO|YYm= MkGxNVAxKM7:TR?= MU[yOEBp NWCyT2RqTE2VTx?= NHLhPHNKSzVyPUCuNVIxKM7:TR?= M{i0clIzOjd2M{m5
U87 MYfDfZRwfG:6aXOgRZN{[Xl? NUjuS5VvOTByIN88US=> MkDmNlQhcA>? M{TFVGROW09? MmLHTWM2OD1yLkGwOUDPxE1? M2HSPVIzOjd2M{m5
U251 M3fKSmN6fG:2b4jpZ{BCe3OjeR?= MkHnNVAxKM7:TR?= MVKyOEBp NVzpZmZpTE2VTx?= M1i4VmlEPTB;MD6xNFAh|ryP M2Hv[|IzOjd2M{m5
T98 MXLDfZRwfG:6aXOgRZN{[Xl? NXOz[ZNROTByIN88US=> NWDZeFJnOjRiaB?= NHnsXmFFVVOR NX7HPXdtUUN3ME2wMlEzPSEQvF2= NEizbIczOjJ5NEO5PS=>
LN18 NGK0bHJEgXSxdH;4bYMhSXO|YYm= MnfDNVAxKM7:TR?= Mn\wNlQhcA>? MYfEUXNQ MnfITWM2OD1yLkKxNEDPxE1? Ml7FNlIzPzR|OUm=
LN443 MV;DfZRwfG:6aXOgRZN{[Xl? MY[xNFAh|ryP MnHKNlQhcA>? NYfNcVM2TE2VTx?= NF70PFBKSzVyPUCuNlIxKM7:TR?= NV\MZ2tHOjJ{N{SzPVk>
HF66 MkPxR5l1d3SxeHnjJGF{e2G7 M4fR[lExOCEQvF2= NXLHVlRmOjRiaB?= MYTEUXNQ MojNTWM2OD1yLkKyOUDPxE1? M4nreVIzOjd2M{m5
HF2303 NGPVVZBEgXSxdH;4bYMhSXO|YYm= M1zLdlExOCEQvF2= Mnz1NlQhcA>? NH;nb4RFVVOR NV7QUoFGUUN3ME2wMlA3OCEQvF2= NHH2ZWwzOjJ5NEO5PS=>
HF2359 MX7DfZRwfG:6aXOgRZN{[Xl? NWfneolUOTByIN88US=> NVTqPWZsOjRiaB?= M2nWOGROW09? MljvTWM2OD1yLkC2NEDPxE1? MVyyNlI4PDN7OR?=
HF2414 M4f0O2N6fG:2b4jpZ{BCe3OjeR?= MUixNFAh|ryP NWrOeHpuOjRiaB?= NF\0TlRFVVOR MVvJR|UxRTBwMEiwJO69VQ>? MlzUNlIzPzR|OUm=
A-673 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Sy[VExKM7:TR?= NF6wN4Q6PiCq NX7IeWd6TE2VTx?= NEH1b4FKSzVyPUCuNFMzKM7:TR?= MXWyNVQ1QDV7MR?=
TC-32 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3SNVAh|ryP MYG5OkBp MnL2SG1UVw>? NVTWfVFKUUN3ME2wMlA{QSEQvF2= MlnmNlE1PDh3OUG=
TC-71 M3O1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\CelExKM7:TR?= NXzYSnh[QTZiaB?= MlHhSG1UVw>? MWXJR|UxRTBwMUCyJO69VQ>? MWCyNVQ1QDV7MR?=
SK-N-MC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPPNVAh|ryP NFHXSoI6PiCq MlS3SG1UVw>? MlTHTWM2OD1yLkC3NkDPxE1? NH3MOJUzOTR2OEW5NS=>
CHLA-9 M4DkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLZXowyOCEQvF2= MoDYPVYhcA>? NH3JZ5JFVVOR NILZPVlKSzVyPUCuNFE5KM7:TR?= MVeyNVQ1QDV7MR?=
CHLA-10 M2P4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2xNEDPxE1? M{jiTlk3KGh? MX;EUXNQ M{mxe2lEPTB;MD6wOlAh|ryP MX[yNVQ1QDV7MR?=
CHLA-25 Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPpOVYyOCEQvF2= Ml[0PVYhcA>? M4nGTGROW09? MoPvTWM2OD1yLkG2PEDPxE1? NFrmdHAzOTR2OEW5NS=>
CHLA-32 M1;uNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\6VoRvOTBizszN MWC5OkBp MlT2SG1UVw>? MofNTWM2OD1yLkGzOkDPxE1? M33PZVIyPDR6NUmx
CHLA-56 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWxNEDPxE1? M2n6R|k3KGh? NHjSV|dFVVOR MWDJR|UxRTFyIN88US=> M3rhOFIyPDR6NUmx
CHLA-258 NUf3c2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHuToQyOCEQvF2= NV;GU|NiQTZiaB?= MU\EUXNQ MVXJR|UxRTBwMUOyJO69VQ>? MXSyNVQ1QDV7MR?=
COG-E-352 NIjn[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNEDPxE1? NV34d4ZvQTZiaB?= NEXm[oFFVVOR NUXXfphnUUN3ME2wMlA1OyEQvF2= Mk\JNlE1PDh3OUG=
CHLA-90 M1zvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPFW3VGOTBizszN NYfyZZlzQTZiaB?= NXL1fFNpTE2VTx?= M3[3NmlEPTB;MD6wOlEh|ryP M3z5SVIyPDR6NUmx
CHLA-119 NYroVGRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNEDPxE1? M3joW|k3KGh? M4LaXWROW09? MUnJR|UxRTBwMEKyJO69VQ>? NX\CdZZWOjF2NEi1PVE>
CHLA-122 NVKyNpluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxNEDPxE1? MX25OkBp NGLqSmNFVVOR NVO2XIc4UUN3ME2wMlAyQSEQvF2= MlnHNlE1PDh3OUG=
CHLA-136 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPXNVAh|ryP NEP1fJQ6PiCq NVTtdmdtTE2VTx?= MYLJR|UxRTBwMEO5JO69VQ>? MXiyNVQ1QDV7MR?=
CHLA-140 NFTZRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf3c5MyOCEQvF2= NV7Deo05QTZiaB?= MYfEUXNQ M2HqeWlEPTB;MD6wNlYh|ryP NW\idpFwOjF2NEi1PVE>
LA-N-6 NYfCSFV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrOZVgyOCEQvF2= NGXyU286PiCq M1XIPWROW09? NYewe2lwUUN3ME2wMlA2PCEQvF2= MYWyNVQ1QDV7MR?=
NB-1643 M3HpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknHNVAh|ryP MWi5OkBp MXjEUXNQ NWTKO|c4UUN3ME2wMlA{PyEQvF2= MY[yNVQ1QDV7MR?=
NB-EBc1 M4fNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qyNVExKM7:TR?= MYm5OkBp M4\Re2ROW09? NFvzSXFKSzVyPUCuNFUxKM7:TR?= NGnFbogzOTR2OEW5NS=>
SK-N-BE-1 NHnURZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXCNVAh|ryP NWnYNZk6QTZiaB?= MojkSG1UVw>? NV3OcnJYUUN3ME2wMlAzQCEQvF2= MX2yNVQ1QDV7MR?=
SK-N-BE-2 NIWzXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKxNEDPxE1? M3XNfVk3KGh? MUDEUXNQ MlzPTWM2OD1yLkCzOkDPxE1? MnHFNlE1PDh3OUG=
SMS-KAN M4DUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISycJgyOCEQvF2= MYO5OkBp M1;mbWROW09? NXftRo5ZUUN3ME2wMlA{PCEQvF2= NF;iN5YzOTR2OEW5NS=>
SMS-KANR MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDrZmsyOCEQvF2= MUi5OkBp NX2zVVRMTE2VTx?= NGn6S5RKSzVyPUCuNFI3KM7:TR?= MVWyNVQ1QDV7MR?=
SMS-KCN NF;XTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnBNVAh|ryP MUC5OkBp MmXOSG1UVw>? M1T1dGlEPTB;MD6wNVkh|ryP MXuyNVQ1QDV7MR?=
SMS-KCNR MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX6e3cyOCEQvF2= NHXqS|A6PiCq M{jTdWROW09? NE\iWVVKSzVyPUCuNFExKM7:TR?= NUDUSXh5OjF2NEi1PVE>
SMS-LHN M4XPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjqWY81OTBizszN NH;5UGM6PiCq NWPSW|NOTE2VTx?= M1zXUGlEPTB;MD6wN|Ih|ryP NXjITGdbOjF2NEi1PVE>
SMS-MSN MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv0[HkyOCEQvF2= MVO5OkBp MoLISG1UVw>? Mn[5TWM2OD1yLkCyNkDPxE1? NVjMXFZiOjF2NEi1PVE>
SMS-SAN M2n2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XyUVExKM7:TR?= MYq5OkBp M{jmO2ROW09? M1G2N2lEPTB;MD6wNlAh|ryP M{PPVVIyPDR6NUmx
Granta-4 NYHhPVNJS3m2b4TvfIlkKEG|c3H5 MWWxNEDPxE1? NWr6cGtUPyCm MomyTWM2OD1yLkC0NEDPxE1? NXm3WG5YOjF{OUG4Olc>
DB M1qwOmN6fG:2b4jpZ{BCe3OjeR?= M1y4VVExKM7:TR?= NWfBVVZ{PyCm NUfwXo1yUUN3ME2wMlA1OiEQvF2= M{\GdVIyOjlzOE[3
RL NHXUXJVEgXSxdH;4bYMhSXO|YYm= MYCxNEDPxE1? NX7v[XFWPyCm NITH[HJKSzVyPUCuNFE2KM7:TR?= MkPwNlEzQTF6Nke=
K562 MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDnNVAh|ryP NEHMfpI6PiCq MVHJR|UxRTBwMEi3JO69VQ>? M{fEVFIyODlzNkOz
LAMA-84 NWLy[4NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Dlb|ExKM7:TR?= NHjKXYg6PiCq NV;CVmlMUUN3ME2wMlA2PyEQvF2= MXqyNVA6OTZ|Mx?=
MM15 NUm3OGx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi3OoY1KM7:TR?= M1HqNlczKGh? NEHZRZZFVVOR MnvLTWM2OD1yLkGzJO69VQ>? MYiyNFM5Ojh2NB?=
OPM1 NYLLbWhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jGblQh|ryP M1[3ZVczKGh? MornSG1UVw>? MUHJR|UxRTBwMEOg{txO Ml;mNlA{QDJ6NES=
RPM1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;wV3lJPCEQvF2= NY\0S5FKPzJiaB?= NXP4PJh5TE2VTx?= NILtUINKSzVyPUGwMlMzKM7:TR?= Mmr2NlA{QDJ6NES=
INA6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVu0JO69VQ>? M{f4O|czKGh? NFvCb4lFVVOR NHS5d4xKSzVyPUCuNFAzKM7:TR?= MWCyNFM5Ojh2NB?=
OPM2 NUjQO3MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm1SFQ1KM7:TR?= NFL4eIE4OiCq Mk\QSG1UVw>? NFnteZVKSzVyPUSuN|ch|ryP M4DhOlIxOzh{OES0
MM1R NWX2RYY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Wx[VQh|ryP M4\QWlczKGh? Moj3SG1UVw>? M1K2cGlEPTB;MT62PEDPxE1? NVfYOGx3OjB|OEK4OFQ>
DOX40 M3;JXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj4OEDPxE1? MWS3NkBp MorPSG1UVw>? NHrpWotKSzVyPUWuOFgh|ryP MX[yNFM5Ojh2NB?=
LR5 NHvjSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPM[o9RPCEQvF2= NWPkUmhOPzJiaB?= NIL2VpRFVVOR NIr4OZVKSzVyPUKuOVMh|ryP Mm\TNlA{QDJ6NES=
U266 M3vPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUK0JO69VQ>? M3izZ|czKGh? NVvGWWxITE2VTx?= M1;kNmlEPTB;MT60N{DPxE1? NYrxeWdMOjB|OEK4OFQ>
RD NVTQV4o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3ke5YyOCEQvF2= M3\HUlk3KGh? MYPJR|UxRTBwMkK4JO69VQ>? NG\nRlczODFyOEOzPC=>
Rh41 NEPFT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[0O3QyOCEQvF2= MWm5OkBp MVPJR|UxRTBwMEmwJO69VQ>? M1;QV|IxOTB6M{O4
Rh30 NIfTXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fHdVExKM7:TR?= MmjlPVYhcA>? NVflUFBGUUN3ME2wMlI{OCEQvF2= MnfHNlAyODh|M{i=
BT-12 NYPZTo1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[xNVAh|ryP M2ixVVk3KGh? M3\qXmlEPTB;MD6wOlAh|ryP MlHDNlAyODh|M{i=
CHLA-266 M3\mdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? MXe5OkBp NVnJWWRWUUN3ME2wMlA4OiEQvF2= M4PWN|IxOTB6M{O4
TC-71 NYrOT2FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j3NlExKM7:TR?= NFLiWIE6PiCq M{C0SmlEPTB;MD6xNFIh|ryP NVn2XnlYOjBzMEizN|g>
SJ-GBM2 M1nLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxNEDPxE1? M{KwWlk3KGh? MWTJR|UxRTBwMEWwJO69VQ>? NXXjVIszOjBzMEizN|g>
NALM-6 NYXISmJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXBNVAh|ryP NWfZ[HRCQTZiaB?= M4K0bGlEPTB;MD6wOlIh|ryP MY[yNFExQDN|OB?=
COG-LL-317 NGHEW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WyZ|ExKM7:TR?= NUTaWFE3QTZiaB?= NEDGTHZKSzVyPUCuNFQ4KM7:TR?= MoHjNlAyODh|M{i=
RS4-11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:3dWtWOTBizszN MUm5OkBp M{jzVWlEPTB;MD6wNVgh|ryP NYHaS3dqOjBzMEizN|g>
MOLT-4 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnLe5kyOCEQvF2= NWPYZ45bQTZiaB?= NIXZWoFKSzVyPUCuNFI3KM7:TR?= NXf0UpJMOjBzMEizN|g>
CCRF-CEM MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHLUYpqOTBizszN NUHFOpVLQTZiaB?= NFzFXXNKSzVyPUCuNFk1KM7:TR?= MYGyNFExQDN|OB?=
Kasumi-1 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;K[4QyOCEQvF2= NGW3RYg6PiCq NEixOHZKSzVyPUCuNVA{KM7:TR?= NUXmPVNiOjBzMEizN|g>
Karpas-299 NUXOSZMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17VN|ExKM7:TR?= MoDvPVYhcA>? NXmzSpBLUUN3ME2wMlA{QCEQvF2= MUOyNFExQDN|OB?=
Ramos-RA1 NVjCfo93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvOO2hqOTBizszN NFixdFA6PiCq MorOTWM2OD1yLkGyO{DPxE1? Ml;xNlAyODh|M{i=

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
15% Captisol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID